VLTR 621
Alternative Names: VLTR-621Latest Information Update: 18 Jul 2023
Price :
$50 *
At a glance
- Originator Valitor
- Class Anti-inflammatories; Drug conjugates
- Mechanism of Action Tumour necrosis factor inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Joint disorders
Most Recent Events
- 18 Jul 2023 Discontinued - Preclinical for Joint disorders in USA (Valitor pipeline, July 2023)
- 13 Oct 2022 Preclinical trials in Joint disorders in USA (Valitor pipeline, October 2022)